^Ad hoc notification pursuant to Art. 53 LR
Pratteln, Switzerland, May 31, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the
Release of the 2022 annual report with the fully audited
Announced results for the year ended December 31, 2022.
The annual report 2022 provides comprehensive and detailed information about this
company, the strategy, the course of business, the financial performance,
corporate governance and compensation in 2022 and confirms that
Preliminary, unaudited 2022 annual results published on April 27, 2023
became. The annual report 2022 (English) is available on the company’s website
at www.santhera.de/financial-reports (http://www.santhera.de/financial-
reports) ready for download.
corporate calendar
June 27, 2023 General Assembly
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss company
Specialty pharmaceutical company focused on the development and commercialization of
innovative medicines for rare neuromuscular and pulmonary diseases
with high medical needs. The company owns one
exclusive license for all indications worldwide for vamorolone
dissociative steroid with a novel mode of action, which in a
Pivotal study in patients with Duchenne muscular dystrophy (DMD).
alternative to standard corticosteroids. For vamorolone to
Santhera has FDA treatment for DMD
an application for approval (NDA) or at the European Medicines Agency (EMA)
a Marketing Authorization Application (MAA) under review and with the UK
Medicines and Healthcare products Regulatory Agency (MHRA)
submitted an MAA. The clinical pipeline also includes lonodelestat for
Treatment of cystic fibrosis (CF) and other neutrophils
lung diseases. Santhera has the rights to its first approved product,
Raxone® (idebenone), outside North America and France for the treatment of
Leber’s hereditary optic neuropathy (LHON) out-licensed to the Chiesi Group.
For more information, please visit www.santhera.com.
Raxone(®) is a trademark of Santhera Pharmaceuticals.
For more information please contact:
[email protected] (mailto:[email protected]) or
Eva Kalias, Head of Investor Relations & Communications
Phone: +41 79 875 27 80
[email protected] (mailto:[email protected])
Disclaimer / Forward-Looking Statements
This communication constitutes neither an offer nor an invitation to subscribe
or to purchase securities of Santhera Pharmaceuticals Holding AG.
This publication may contain certain forward-looking statements about the
Company and its operations included. Such statements are with
certain risks, uncertainties and other factors involved
can lead to actual results, financial condition, achievements
or achievements of the company differ materially from those which
expressed or implied in these statements. Readers should
therefore, do not place undue reliance on these statements, particularly
not in connection with contracts or investment decisions. The
Company disclaims any obligation to update these forward-looking statements
To update.
# # #
°
Leverage must be between 2 and 20
No data